Open figure viewer
Wanbang Pharmaceutical Technology is a CRO (contract research organization) providing pharmaceutical research and clinical trial services. After two industry shocks and an internal reorganization, the company grew rapidly and went public on the Shenzhen ChiNext board in 2023. Founder Chunlei Tao now hopes to leverage the listing to attract talent, energize the organization, and steer the company's transformation from a traditional CRO toward the broader healthcare sector. How should Wanbang design an organization that aligns with this strategic transition?
© School of Management, Fudan University
2026
School of Management, Fudan University
Cases are developed as the basis for class discussion and public reading. Cases are not intended to serve as endorsements, sources of primary data, or illustrations of effective or ineffective management. No part of this publication may be reproduced, copied, stored, transmitted or sold in any form or by any means without the permission of School of Management, Fudan University. To request permission to reproduce materials, please call +86-21-2501 1399, or email to case@fdsm.fudan.edu.cn. This case was funded by Fudan premium Fund of Management. For more case information, please go to http://case.fdsm.fudan.edu.cn/.
You do not currently have access to this content.
